BPC-157 (Body Protection Compound-157) is a synthetic peptide fragment derived from a sequence identified in gastric juice. It is not an FDA-approved drug and has no United States Pharmacopeia (USP) monograph. In practice it is discussed almost entirely in the context of research and compounding rather than any approved therapy.
Despite the absence of an approval, BPC-157 ranks as the #5 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. That ranking sits alongside an unusually active regulatory picture: BPC-157 was removed from FDA's Category 2 bulk-substance table in April 2026 and is scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) in July 2026. For prescribing clinicians, the regulatory context matters more here than for almost any other compounded item, and it is the focus of this page.
What BPC-157 Is
BPC-157 is a 15-amino-acid peptide corresponding to a partial sequence of a protein isolated from gastric juice. It is often described in the preclinical literature as a "pentadecapeptide." Vendors and some clinics market it under a broad "tissue repair" or "gut and musculoskeletal recovery" heading, but it is important to separate marketing framing from the evidence base.
The published human evidence for BPC-157 is limited. Most of the available data comes from animal models and in-vitro studies, and there are few controlled human trials establishing clinical outcomes. This page does not assert any therapeutic benefit, and providers evaluating BPC-157 should treat claims of tissue "healing" or systemic recovery — which are common in direct-to-consumer peptide marketing — as unsupported by the current regulatory and clinical record.
BPC-157 exists in more than one chemical form. FDA has separately identified BPC-157 free base and BPC-157 acetate, reflecting that chemical identity, salt form, stability, and impurity profile can differ between preparations and are relevant to any compounding evaluation.
How Providers Use It in Practice
BPC-157 is ordered primarily by clinics operating in the peptide, longevity, sports-medicine, and regenerative-wellness space. Some providers in musculoskeletal and recovery-oriented practices express interest in it as part of a broader peptide offering, and some gastroenterology-adjacent and integrative practices reference it as part of their own research-oriented interest rather than any approved use.
Because BPC-157 is not FDA-approved for any indication, any clinical use falls outside an approved labeling framework. Providers who consider it are responsible for their own clinical rationale, informed-consent process, and documentation, and for confirming that a given preparation can be lawfully compounded at all — a question addressed directly in the regulatory section below. This page describes the practice context in neutral terms and does not recommend BPC-157 for any use.
Forms and Combinations Available Through Compounding
Where BPC-157 is compounded, it is typically prepared as a sterile injectable solution or lyophilized powder for reconstitution, and it is also prepared in oral formats such as capsules, troches, and tablets. Compounding, in principle, exists to allow a licensed pharmacist to prepare a patient-specific preparation when an approved product does not meet a documented individual need — for example, a specific concentration, excipient profile, or route.
For BPC-157 specifically, the threshold question is not the dosage form but whether the bulk active ingredient is eligible for compounding under federal law. As discussed below, BPC-157 does not currently sit on either the 503A bulk-drug-substances list or the 503B bulks list, which constrains the pathways under which it could be compounded regardless of the form requested. No dosing, strength, or administration guidance is provided here.
Regulatory Status and Provider Considerations
This is the core of the BPC-157 picture, and it is in active motion as of July 2026.
Not FDA-approved, no USP monograph. BPC-157 is not an approved drug and does not have a USP-NF monograph. For a bulk substance to be eligible for 503A compounding, it generally must be the subject of an applicable USP monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulk-drug-substances (the "503A Bulks List"). BPC-157 currently meets none of these on a settled basis.
Category 2 history. FDA had previously placed BPC-157 in Category 2 of its interim bulk-substances framework — the tier for substances that raise significant safety concerns for compounding. FDA's stated concerns for BPC-157 have historically centered on immunogenicity (the potential for the immune system to recognize a peptide, aggregate, or impurity as foreign) and on incomplete characterization of chemical identity, stability, and impurities. Category 2 status meant FDA did not intend to exercise enforcement discretion for compounding the substance while that concern stood.
April 2026 removal from Category 2. In April 2026, FDA removed BPC-157 (along with several other peptides) from the Category 2 table after the underlying nomination was withdrawn and FDA indicated it would bring the substance before PCAC. This procedural removal is widely misreported. Removal from Category 2 does not mean BPC-157 has been cleared, approved, or moved to Category 1, and it does not resolve the earlier safety questions. It reflects a change in the review posture, not a favorable safety determination.
July 2026 PCAC review. BPC-157 is scheduled for evaluation by the Pharmacy Compounding Advisory Committee at its July 2026 meeting, where the committee is expected to consider whether BPC-157 free base and BPC-157 acetate should be added to the 503A Bulks List, with characterization and safety among the questions in scope. PCAC is an advisory body: it makes recommendations to FDA and does not itself write the final rule. A favorable committee vote would not place BPC-157 on the Bulks List immediately, and an unfavorable one would leave its status unresolved.
503B. BPC-157 does not appear on FDA's 503B bulks list, which governs bulk substances that outsourcing facilities may compound. As of July 2026 there is no settled federal pathway that authorizes BPC-157 compounding for general use.
The practical takeaway for providers, stated plainly: as of July 2026, BPC-157's compounding eligibility is unsettled and under active FDA review. Clinicians should verify current federal status, any applicable state board positions, and the specific pharmacy's compliance posture before relying on it, and should revisit the question after the PCAC outcome is published. None of the above should be read as a statement that BPC-157 is approved, safe, or effective.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Where a licensed pharmacy prepares BPC-157 within its own compliance determination, the same sourcing and quality questions that apply to any sterile peptide apply here — with added weight given the immunogenicity and characterization concerns FDA has raised:
- API source and Certificate of Analysis (CoA): Where is the active ingredient sourced, and can the pharmacy provide a lot-specific CoA identifying the exact form (free base vs. acetate), purity, and impurity profile?
- Identity and characterization: How is peptide identity and sequence confirmed, and how are related impurities and aggregation assessed — the specific issues underlying FDA's historical concern?
- USP <795>, <797>, and <800> compliance: Does the facility document compliance with the applicable non-sterile, sterile, and hazardous-compounding standards?
- Potency and sterility testing: Are finished-preparation potency, sterility, and endotoxin testing performed, and are results available?
- Beyond-use dating: How is beyond-use dating assigned and supported for the specific formulation?
- State licensure and status verification: Is the pharmacy appropriately licensed in the dispensing state, and can it articulate how it is treating BPC-157's federal eligibility in light of the July 2026 PCAC review?
Clinics order compounded medications through platforms like ScriptLinkRx that connect licensed practices with licensed compounding pharmacies, but the eligibility and clinical-rationale determinations remain the responsibility of the prescriber and the dispensing pharmacy.
Frequently Asked Questions
Is BPC-157 FDA-approved?
No. As of July 2026, BPC-157 is not an FDA-approved drug for any indication and has no USP monograph. It is not equivalent to any branded or approved product.
Does the April 2026 Category 2 removal mean BPC-157 is now cleared for compounding?
No. Removal from the Category 2 table was procedural, tied to a withdrawn nomination and a planned PCAC review. It did not grant Category 1 status, resolve FDA's earlier safety concerns, or authorize compounding. Eligibility remains unsettled.
Is BPC-157 legal for a clinic to prescribe?
The lawful pathway question turns on whether the bulk substance is eligible for compounding, which is currently unresolved and under FDA review. Providers should verify current federal status, state board positions, and the dispensing pharmacy's compliance determination rather than assume eligibility. This page does not provide legal advice.
What is the significance of the July 2026 PCAC meeting?
PCAC is expected to consider whether BPC-157 free base and acetate should be added to the 503A Bulks List. Its role is advisory; any change to BPC-157's status would follow FDA's own rulemaking after the committee's recommendation.
Is there strong human evidence for BPC-157?
Published human evidence is limited. Most data comes from preclinical and animal studies, and marketing claims of tissue repair or recovery are not supported by an established clinical or regulatory record.
Related Reading
- See where BPC-157 ranks among the most-prescribed compounded medications
- TB-500: compounding and regulatory status for providers
- GHK-Cu copper peptide: what providers should know
